Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA advisory committee

This article was originally published in The Tan Sheet

Executive Summary

The Risk Communication Advisory Committee will meet May 15-16, 2008, in Rockville, Md., to discuss direct-to-consumer advertising, including how it relates to subsets of the population and the appropriateness of statements in the ads that encourage consumers to report negative side effects of prescription drugs to MedWatch, according to an FDA notice in the April 28 Federal Register. Consumers or groups interested in presenting oral comments should submit their position and arguments to the agency by May 8. Comments submitted through June 16 will be considered for a report on the issue, the agency says...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS101587

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel